cyc 682 has been researched along with Leukemia, Myeloid, Acute in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czemerska, M; Robak, T; Wierzbowska, A | 1 |
| Byrd, JC; Lai, TH; Lapalombella, R; Liu, C; Mims, A; Mitchell, S; Orwick, S; Plunkett, W; Puduvalli, VK; Ravikrishnan, J; Sampath, D; Woyach, J; Wu, PJ | 1 |
| Lancet, JE | 1 |
| Jamieson, K; Lim, MY | 1 |
| Burnett, AK; Cahalin, P; Clark, RE; Hemmaway, C; Hills, RK; Khwaja, A; Milligan, D; Panoskaltsis, N; Russell, N | 1 |
| Norkin, M; Richards, AI | 1 |
| Blachly, JS; Ewald, B; Garzon, R; Lai, TH; Liu, C; Papaioannou, D; Plunkett, W; Sampath, D; Sulda, M; Zecevic, A | 1 |
| Choudhary, AK; Fleming, IN; Green, SR | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Baer, MR; Gojo, I | 1 |
| Burnett, AK; Hills, RK | 1 |
| Arellano, M; Chiao, J; Claxton, D; Coutre, S; Faderl, S; Garcia-Manero, G; Goldberg, SL; Jabbour, E; Kantarjian, H; Luger, S; Maness, L; Plunkett, W; Schiller, G; Seiter, K; Stock, W; Strickland, SA; Venugopal, P; Wetzler, M | 1 |
| Russell, NH | 1 |
| Faderl, S; Gandhi, V; Kantarjian, HM | 1 |
5 review(s) available for cyc 682 and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
The efficacy of sapacitabine in treating patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Arabinonucleosides; Cytosine; Humans; Leukemia, Myeloid, Acute; Prognosis; Treatment Outcome | 2018 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Cytosine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2014 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytosine; Dioxolanes; Humans; Leukemia, Myeloid, Acute; Nucleosides | 2008 |
2 trial(s) available for cyc 682 and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cytarabine; Cytosine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate | 2015 |
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Arabinonucleosides; Cytosine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Pneumonia; Thrombocytopenia | 2012 |
7 other study(ies) available for cyc 682 and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzamides; Cell Line, Tumor; Cytosine; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Leukemia, Myeloid, Acute | 2019 |
Sapacitabine in the treatment of acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arabinonucleosides; Cytosine; Humans; Leukemia, Myeloid, Acute; Prognosis; Treatment Outcome | 2015 |
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Topics: Apoptosis; Arabinonucleosides; Cell Line, Tumor; Cytosine; DNA Damage; Gene Expression; HeLa Cells; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Promoter Regions, Genetic; Rad51 Recombinase; Recombinational DNA Repair | 2016 |
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line, Tumor; Cytosine; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Neoplasms; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Improving outcomes for elderly patients with AML.
Topics: Arabinonucleosides; Cytosine; Female; Humans; Leukemia, Myeloid, Acute; Male | 2012 |